MX2018001032A - Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr. - Google Patents

Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.

Info

Publication number
MX2018001032A
MX2018001032A MX2018001032A MX2018001032A MX2018001032A MX 2018001032 A MX2018001032 A MX 2018001032A MX 2018001032 A MX2018001032 A MX 2018001032A MX 2018001032 A MX2018001032 A MX 2018001032A MX 2018001032 A MX2018001032 A MX 2018001032A
Authority
MX
Mexico
Prior art keywords
pdgfr
kit
disorders related
treating disorders
compounds useful
Prior art date
Application number
MX2018001032A
Other languages
English (en)
Inventor
L Hodous Brian
Zhang Yulian
J Wilson Kevin
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of MX2018001032A publication Critical patent/MX2018001032A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se describen en la presente compuestos de fórmula I y composiciones de estos útiles para el tratamiento de trastornos relacionados con KIT y PDGFR.
MX2018001032A 2015-07-24 2016-07-21 Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr. MX2018001032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562196445P 2015-07-24 2015-07-24
PCT/US2016/043301 WO2017019442A1 (en) 2015-07-24 2016-07-21 Compounds useful for treating disorders related to kit and pdgfr

Publications (1)

Publication Number Publication Date
MX2018001032A true MX2018001032A (es) 2018-11-09

Family

ID=56555836

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001032A MX2018001032A (es) 2015-07-24 2016-07-21 Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.

Country Status (17)

Country Link
US (2) US10000496B2 (es)
EP (1) EP3325481B1 (es)
JP (1) JP2018521076A (es)
KR (1) KR20180048635A (es)
CN (1) CN108026102A (es)
AR (1) AR105459A1 (es)
AU (1) AU2016297754A1 (es)
BR (1) BR112018001190A2 (es)
CA (1) CA2994819A1 (es)
HK (1) HK1255103A1 (es)
IL (1) IL256978A (es)
MX (1) MX2018001032A (es)
PH (1) PH12018500177A1 (es)
RU (1) RU2018106483A (es)
TW (1) TW201704237A (es)
WO (1) WO2017019442A1 (es)
ZA (1) ZA201801019B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2872491T3 (da) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
DK3057969T3 (en) 2013-10-17 2018-09-24 Blueprint Medicines Corp COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT
EP3060560A1 (en) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
CA2995997A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
LT3371171T (lt) 2015-11-02 2024-01-10 Blueprint Medicines Corporation Ret inhibitoriai
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
HUE063042T2 (hu) 2016-04-15 2023-12-28 Blueprint Medicines Corp Az aktivin receptorszerû kináz inhibitorai
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
AU2018255191B2 (en) * 2017-04-18 2022-04-21 Eli Lilly And Company Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
WO2019079649A1 (en) 2017-10-18 2019-04-25 Blueprint Medicines Corporation SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
CN107868823A (zh) * 2017-10-31 2018-04-03 天津协和华美医学诊断技术有限公司 一种检测mds/mpn相关基因群的检测试剂盒
KR20200139749A (ko) 2018-04-03 2020-12-14 블루프린트 메디신즈 코포레이션 Ret 변경을 갖는 암을 치료하는 데 사용하는 데 사용하기 위한 ret 억제제
MX2021012469A (es) 2019-04-12 2022-01-18 Blueprint Medicines Corp Composiciones y metodos para el tratamiento de enfermedades mediadas por kit y pdgfra.
GB201915447D0 (en) * 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
DE60042620D1 (de) * 1999-05-21 2009-09-03 Bristol Myers Squibb Co Pyrrolotriazine als Kinase Hemmer.
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
MX2008009557A (es) 2006-01-27 2009-01-07 Shanghai Hengrui Pharm Co Ltd Inhibidores de la cinasa de proteina de la pirrolo [3,2-c] piridin-4-ona-2-indolinona.
JP5185930B2 (ja) * 2006-07-07 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤
WO2009015254A1 (en) 2007-07-25 2009-01-29 Bristol-Myers Squibb Company Triazine kinase inhibitors
CA2716856C (en) 2008-03-20 2013-02-19 Amgen Inc. Aurora kinase modulators and method of use
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
CN102573486A (zh) 2009-06-08 2012-07-11 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US9334269B2 (en) 2010-02-17 2016-05-10 Amgen Inc. Carboxamides as inhibitors of voltage-gated sodium channels
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
DK2872491T3 (da) 2012-07-11 2021-08-09 Blueprint Medicines Corp Inhibitorer af fibroblastvækstfaktorreceptoren
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
US9499522B2 (en) 2013-03-15 2016-11-22 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
DK3057969T3 (en) 2013-10-17 2018-09-24 Blueprint Medicines Corp COMPOSITIONS USED FOR TREATMENT OF DISEASES RELATED TO ENZYMETE KIT
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
EP3060560A1 (en) 2013-10-25 2016-08-31 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2016022569A1 (en) * 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
AU2016297754A1 (en) 2015-07-24 2018-02-15 Blueprint Medicines Corporation Compounds useful for treating disorders related to KIT and PDGFR
CA2995997A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
LT3371171T (lt) 2015-11-02 2024-01-10 Blueprint Medicines Corporation Ret inhibitoriai
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
US10183928B2 (en) 2016-03-17 2019-01-22 Blueprint Medicines Corporation Inhibitors of RET
HUE063042T2 (hu) 2016-04-15 2023-12-28 Blueprint Medicines Corp Az aktivin receptorszerû kináz inhibitorai

Also Published As

Publication number Publication date
US10000496B2 (en) 2018-06-19
HK1255103A1 (zh) 2019-08-02
TW201704237A (zh) 2017-02-01
AU2016297754A1 (en) 2018-02-15
ZA201801019B (en) 2019-04-24
EP3325481B1 (en) 2019-06-12
CA2994819A1 (en) 2017-02-02
PH12018500177A1 (en) 2018-07-30
WO2017019442A1 (en) 2017-02-02
EP3325481A1 (en) 2018-05-30
US20170022206A1 (en) 2017-01-26
AR105459A1 (es) 2017-10-04
JP2018521076A (ja) 2018-08-02
RU2018106483A (ru) 2019-08-26
IL256978A (en) 2018-03-29
CN108026102A (zh) 2018-05-11
BR112018001190A2 (pt) 2018-09-11
US20190119280A1 (en) 2019-04-25
KR20180048635A (ko) 2018-05-10

Similar Documents

Publication Publication Date Title
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201892147A1 (ru) Бициклические соединения
PH12016500611A1 (en) Compositions useful for treating disorders related to kit
MX2020003702A (es) Ciclopropilaminas como inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
MX2017008444A (es) Picolinamidas como fungicidas.
EA201891251A1 (ru) Бициклические ингибиторы pad4
MA40076A (fr) Inhibiteurs de syk
TW201613853A (en) Synthesis of polycyclic-carbamoylpyridone compounds
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
NZ730603A (en) Mk2 inhibitors and uses thereof
NZ711718A (en) Substituted xanthines and methods of use thereof
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
TN2016000542A1 (en) Pyrazole compounds and their use as t-type calcium channel blockers
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201690844A1 (ru) Ингибиторы gsk-3
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MA39824A (fr) Composés azole amido-substitués
EA201790830A1 (ru) Ингибиторы альдостеронсинтазы